The golden ages of inflammatory skin diseases: skyrocketing developments in the therapy of psoriasis and atopic dermatitis
Author:
Open Access
- 14 October 2021
- journal article
- editorial
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (11) , 2239-2240
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysisJournal of the European Academy of Dermatology and Venereology, 2021
- EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendationsJournal of the European Academy of Dermatology and Venereology, 2020
- Topical long‐term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practiceJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2014
- Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologistsJournal of the European Academy of Dermatology and Venereology, 2014
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- The US FDA ‘Black Box’ Warning for Topical Calcineurin InhibitorsDrug Safety, 2008
- 308 nm UVB excimer laser for psoriasisThe Lancet, 1997
- A Short-Term Trial of Tacrolimus Ointment for Atopic DermatitisNew England Journal of Medicine, 1997
- FK506 in the treatment of inflammatory skin disease: promises and perspectivesImmunology Today, 1996
- Dithranol: A Review of the Mechanism of Action in the Treatment of Psoriasis vulgarisSkin Pharmacology and Physiology, 1990